Back to top

Analyst Blog

Incyte Corporation (INCY - Analyst Report) recently announced positive long-term data from two ongoing studies on Jakafi. Incyte presented data from the studies at the 18th Congress of the European Hematology Association (EHA) in Stockholm.

Results from a three-year follow-up analysis of the phase III COMFORT-II study showed that the risk of death was reduced by 52% in myelofibrosis (MF) patients treated with Jakafi compared to those treated with the best available therapy. Moreover, reduction in spleen size was also observed in patients treated with Jakafi.

The results from the long-term study further showed that Jakafi was well-tolerated after three years of treatment. Incyte mentioned in its press release that rates of adverse events like anemia and thrombocytopenia decreased over the three-year period. Incyte further stated that the results conformed to the previously reported COMFORT-II and COMFORT-I study results.

Jakafi is the first and only approved treatment for patients suffering from intermediate or high-risk MF in the US. Jakafi (ex-US trade name: Jakavi) is marketed by Novartis (NVS - Analyst Report) outside the US.

Incyte also announced positive results from a phase I/II study (n=68) on Jakafi for the treatment of bone marrow fibrosis in patients suffering from MF. Bone marrow fibrosis is a key feature of MF.

Results from the study showed that bone marrow fibrosis stabilized/improved in most MF patients following long-term treatment with Jakafi. The bone marrow fibrosis stabilization was however not seen in best available therapy, including hydroxyurea.

We note that Incyte is looking to expand Jakafi’s label. It is also being studied for the treatment of polycythemia vera, essential thrombocythemia, solid/other hematologic tumors and pancreatic cancer.

Though encouraged by the company’s lead product, Jakafi we believe its overdependence on the drug for growth may be a cause of concern.

Incyte, a biopharmaceutical company, currently carries a Zacks Rank #3 (Hold). Other biopharma stocks such as Jazz Pharmaceuticals Public Limited Company (JAZZ - Analyst Report) and Santarus, Inc. currently look better positioned with a Zacks Rank #1 (Strong Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
RPC INC RES 24.91 +8.35%
LITHIA MOTO… LAD 94.59 +4.60%
DELTA AIR L… DAL 39.15 +3.90%
FLAMEL TECH… FLML 14.51 +3.50%
SOUTHWEST A… LUV 28.87 +2.92%